Drug Trial Radar · NCT06500793
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Nov 24, 2024
Primary completion
Dec 22, 2026
Study completion Apr 28, 2027
Sponsor
- Lead sponsor
- Ensysce BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Quotient Sciences; National Institute on Drug Abuse (NIDA)
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single dose dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release(ER) capsule prototypes.
Conditions
- Pharmacokinetics
- Healthy Volunteer
Interventions
PF614 capsuleDrug
PF614 capsules (25-100 mg)
Nafamostat MesylateDrug
Nafamostat IR/ER solution/beads/powder (total 1-25 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic Tmax [Time to Maximum Plasma Concentration]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
- Pharmacokinetic Cmax [Maximum Plasma Concentration]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
- Pharmacokinetic C24 [Plasma concentration at 24 hours]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
- Pharmacokinetic AUC(0-last) [Area Under the Curve]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
- Pharmacokinetic AUC(0-inf) [Area Under the Curve]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
- Pharmacokinetic T1/2 [Half-life]Time frame: Parts 1, 2, & 3 (PF614 single dose): predose, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 36, 48, 72 hours.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.